KeyCorp Comments on Evolent Health Inc’s Q1 2018 Earnings (EVH)

Evolent Health Inc (NYSE:EVH) – Investment analysts at KeyCorp increased their Q1 2018 earnings per share (EPS) estimates for Evolent Health in a research note issued on Wednesday. KeyCorp analyst D. Hooker now anticipates that the technology company will post earnings of ($0.02) per share for the quarter, up from their prior forecast of ($0.05). KeyCorp currently has a “Overweight” rating and a $23.00 target price on the stock. KeyCorp also issued estimates for Evolent Health’s Q2 2018 earnings at ($0.01) EPS, Q3 2018 earnings at ($0.01) EPS, FY2018 earnings at ($0.05) EPS and FY2019 earnings at $0.18 EPS.

Evolent Health (NYSE:EVH) last posted its earnings results on Thursday, November 2nd. The technology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.04. Evolent Health had a negative return on equity of 5.05% and a negative net margin of 15.86%. The company had revenue of $107.90 million for the quarter, compared to the consensus estimate of $104.49 million. During the same quarter in the prior year, the business earned ($0.26) earnings per share. The firm’s revenue for the quarter was up 79.2% on a year-over-year basis.

Several other research firms also recently commented on EVH. Zacks Investment Research downgraded Evolent Health from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Cowen reaffirmed an “outperform” rating and issued a $29.00 target price (down previously from $33.00) on shares of Evolent Health in a research report on Friday, October 6th. Canaccord Genuity reaffirmed a “buy” rating and issued a $32.00 target price on shares of Evolent Health in a research report on Friday, October 6th. Robert W. Baird reaffirmed an “outperform” rating and issued a $25.00 target price (down previously from $35.00) on shares of Evolent Health in a research report on Tuesday, September 26th. They noted that the move was a valuation call. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $30.00 target price on shares of Evolent Health in a research report on Wednesday, September 20th. Two analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $28.00.

Evolent Health (EVH) opened at $15.05 on Monday. Evolent Health has a 12-month low of $10.30 and a 12-month high of $27.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.34 and a quick ratio of 3.34. The company has a market capitalization of $1,163.91, a P/E ratio of -13.32 and a beta of 1.07.

A number of large investors have recently modified their holdings of EVH. ETF Managers Group LLC acquired a new stake in Evolent Health during the second quarter worth approximately $102,000. BNP Paribas Arbitrage SA grew its position in Evolent Health by 815.4% during the second quarter. BNP Paribas Arbitrage SA now owns 4,751 shares of the technology company’s stock worth $120,000 after buying an additional 4,232 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Evolent Health during the third quarter worth approximately $156,000. IPG Investment Advisors LLC acquired a new stake in Evolent Health during the third quarter worth approximately $195,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in Evolent Health during the third quarter worth approximately $205,000. 95.38% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “KeyCorp Comments on Evolent Health Inc’s Q1 2018 Earnings (EVH)” was first published by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://weekherald.com/2018/01/15/keycorp-comments-on-evolent-health-incs-q1-2018-earnings-evh.html.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply